Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States

This guideline offers updated, evidence-based recommendations—from preconception through postpartum—on universal prenatal HIV testing, preferred antiretroviral regimens (e.g., bictegravir/TAF/FTC), maternal viral monitoring, obstetric management, and neonatal prophylaxis to further reduce perinatal HIV transmission toward elimination goals (defined as <1% transmission rate and <1 infection per 100,000 live births).